PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE

100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:


Scientific evidence for clinical utility.

By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.

Evidence

Pathologic Complete Response (pCR) Rates According to MammaPrint and BluePrint Results are Consistent Among Pre- and Post-Menopausal Patients

  Publication: Miami Breast  Authors Pat Whitworth, James V Pellicane, Jr., Paul Baron, Peter Beitsch, Laura Lee, Angela Mislowsky, Carrie Dul, Paul Richards, Mark Gittleman, Stephanie Akbari, Shiyu Wang, Andrea Menicucci, Lisa Blumencranz, William Audeh, NBRST Investigators Group. Background Increased use of multi-gene expression profiling has enabled refinement Read More

The FLEX real world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer

Publication: Miami Breast Authors: Pat Whitworth, Jennifer A. Crozier, Robert Maganini, Cathy Graham, Beth-Ann Lesnikoski, Kathryn Wagner, June Lee, Julian Berrocal, Amy M. Truitt, Erin Yoder, Lisa Blumencranz, Bastiaan van der Baan, William Audeh, FLEX Investigators’ Group Background: Genomic expression profiles have implications for the personalized treatment of breast cancer Read More

Racial disparities within Basal-type breast cancer: clinical and molecular features of African American and Caucasian obese patients

  PUBLICATION: SABCS 2020 AUTHORS: Dipali Sharma, Lisa E. Blumencranz, Heather M. Kling, Sahra Uygun, Sarah Untch, William Audeh, Jennifer A. Crozier, Mehran Habibi, and Raquel Nunes Background: African American breast cancer (BC) patients (AA) are diagnosed at a younger age and present more frequently with triple-negative/Basal tumors than Caucasian Read More

Comparing MammaPrint and BluePrint results between core needle biopsy and surgical resection breast cancer specimens

PUBLICATION: SABCS 2020 AUTHORS: Joseph McKelley, Jennifer Wei, Brian Hoxeng, Andrea Menicucci, Erin Yoder, Shiyu Wang, William Audeh Background: Pre-operative/neoadjuvant treatment utilization in early-stage breast cancer has been increasing, particularly during the COVID-19 pandemic. With goals of minimizing potential exposure to SARS-COV-2, as well as resource rationing, physicians are urged Read More

MammaPrint and BluePrint as prognostic indicators for elderly patients with early-stage breast cancer

PUBLICATION: SABCS 2020 AUTHORS: Peter W. Blumencranz, Mehran Habibi, Lisa Blumencranz, Andrea Menicucci, Shiyu Wang, Amy Truitt, William Audeh, Jolanta L. Baginski, Steven Shivers, Geza Acs, Charles E. Cox, MINT Investigators Group. Background: Elderly breast cancer (BC) patients are an understudied population, with limited evidence regarding treatment options and Read More

Differential gene expression in Luminal type invasive lobular carcinoma and invasive ductal carcinoma by MammaPrint risk stratification

PUBLICATION: SABCS 2020 AUTHORS: Beth-Ann Lesnikoski, Jennifer A. Crozier, Gordan Srkalovic, Patricia Robinson, Clodia Osipo, Kalyan Banda, Heather M. Kling, Midas M. Kuilman, Josien Haan, William Audeh, and FLEX Investigators Group Background: Invasive lobular carcinoma (ILC) comprises 10-15% of breast tumors and is the second most common histological type after Read More